Magenta Therapeutics Announces Pricing of Public Offering

Magenta Therapeutics, Inc. (Nasdaq: MGTA), a clinical-stage biotechnology company developing novel medicines to bring the curative power of stem cell transplant to more patients, today announced the pricing of its public offering of 4,250,000 shares of its common stock at a price to the public of $13.25 per share, for total gross proceeds of approximately $56.3 million.

Metadata
Provider: 
Business Wire, Inc.Business Wire, Inc.
Retrieved on: 
Thursday, May 2, 2019
Information
Tags: 
Stem cells, Health, Biotechnology, Genetics, Finance, Money, Financial markets, Corporate finance, Initial public offering, Stock market, Underwriting, Goldman Sachs, Subprime mortgage crisis, Public offering, Stock
Geotags: 
United States, Massachusetts
⚠generated by AI ↴
Summary
Key Points: 
  • Magenta Therapeutics, Inc. (Nasdaq: MGTA), a clinical-stage biotechnology company developing novel medicines to bring the curative power of stem cell transplant to more patients, today announced the pricing of its public offering of 4,250,000 shares of its common stock at a price to the public of $13.25 per share, for total gross proceeds of approximately $56.3 million.
  • In addition, the underwriters have a 30-day option to purchase from Magenta up to 637,500 additional shares of common stock at the public offering price, less underwriting discounts and commissions.
  • The offering is expected to close on May 6, 2019, subject to customary closing conditions.
  • J.P. Morgan, Goldman Sachs & Co. LLC and Cowen are acting as joint book running managers for the offering.


Magenta
Therapeutics, Inc. (Nasdaq: MGTA), a clinical-stage biotechnology
company developing novel medicines to bring the curative power of stem
cell transplant to more patients, today announced the pricing of its
public offering of 4,250,000 shares of its common stock at a price to
the public of $13.25 per share, for total gross proceeds of
approximately $56.3 million. All shares of common stock will be offered
by Magenta. In addition, the underwriters have a 30-day option to
purchase from Magenta up to 637,500 additional shares of common stock at
the public offering price, less underwriting discounts and commissions.
The offering is expected to close on May 6, 2019, subject to customary
closing conditions.

J.P. Morgan, Goldman Sachs & Co. LLC and Cowen are acting as joint book
running managers for the offering. Wedbush PacGrow is acting as lead
manager for the offering.

Important Information

A registration statement relating to the offering has been filed with,
and declared effective by, the United States Securities and Exchange
Commission (“SEC”). The offering of these shares will be made only by
means of a prospectus. Copies of the prospectus can be obtained from:
J.P. Morgan Securities LLC, c/o Broadridge Financial Solutions, 1155
Long Island Avenue, Edgewood, NY 11717, telephone: 866-803-9204; Goldman
Sachs & Co. LLC, Prospectus Department, 200 West Street, New York, NY
10282, telephone: 1-866-471-2526, facsimile: 212-902-9316 or by emailing [email protected];
Cowen and Company, LLC, c/o Broadridge Financial Solutions, 1155 Long
Island Avenue, Edgewood, NY 11717, Attn: Prospectus Department,
telephone: 631-274-2806.

This press release does not constitute an offer to sell or a
solicitation of an offer to buy, nor will there be any offer or sale of
these securities in any state or other jurisdiction in which such offer,
solicitation, or sale would be unlawful prior to the registration or
qualification under the securities laws of any such state or other
jurisdiction.

About Magenta Therapeutics

Headquartered in Cambridge, Mass., Magenta Therapeutics is a
clinical-stage biotechnology company developing novel medicines for
patients with autoimmune diseases, blood cancers and genetic diseases.
By creating a platform focused on critical areas of unmet need, Magenta
Therapeutics is pioneering an integrated approach to allow more patients
to receive one-time, curative therapies by making the process more
effective, safer and easier.

Forward-Looking Statements

This press release contains forward-looking statements that are made
pursuant to the safe harbor provisions within the meaning of Section 27A
of the Securities Act of 1933, as amended, and Section 21E of the
Securities Exchange Act of 1934, as amended. Forward-looking statements
are any statements that express the current beliefs and expectations of
management, including but not limited to statements related to Magenta’s
ability to complete the financing and its use of proceeds. These and
other risks are discussed in Magenta’s filings with the SEC, including,
without limitation, its Annual Report on Form 10-K, filed on March 19,
2019, and its periodic reports on Form 10-Q and Form 8-K, as well as the
risks identified in the registration statement and the preliminary
prospectus supplement relating to the offering. Any statements contained
herein that do not describe historical facts are forward-looking
statements that are subject to risks and uncertainties that could cause
actual results, performance and achievements to differ materially from
those discussed in such forward-looking statements. Moreover, except as
required by law, neither Magenta nor any other person assumes
responsibility for the accuracy and completeness of the forward-looking
statements included in this press release. Any forward-looking statement
included in this press release speaks only as of the date on which it
was made. Magenta undertakes no obligation to publicly update or revise
any forward-looking statement, whether as a result of new information,
future events or otherwise.

Copyright: 
Copyright Business Wire 2019